

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

D. HEINEGÅRD et al.

Application No. 09/609,383

Filed: July 3, 2000

For: CARTILAGE INTERMEDIATE  
LAYER PROTEIN AND  
NUCLEIC ACIDS THEREFOR



Group Art Unit: 1600/2900

Examiner: N/A

TECH CENTER 1600/2900

MAR 08 2001

RECEIVED

Assistant Commissioner for Patents  
Washington, D.C. 20231

OFFICE OF INITIAL PATENT EXAMINATION

REQUEST FOR CORRECTED FILING RECEIPT

We are forwarding herewith a copy of a Filing Receipt for the above-identified patent application. As indicated in red ink on the attached copy, there are two errors in the Filing Receipt. The errors are:

1. The number of independent claims should be 9, not 7.
2. The title is not complete, and should be:  
CARTILAGE INTERMEDIATE LAYER PROTEIN AND  
NUCLEIC ACIDS THEREFOR

It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:

Matthew T. Latimer

Reg. No. 44,024

(202) 408-4495

[matthew.latimer@finnegan.com](mailto:matthew.latimer@finnegan.com)

Date: December 14, 2000

LAW OFFICES


FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N.W.  
WASHINGTON, DC 20005  
202-408-4000

6803.0008  
1CSM/MTL

## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/609,383	07/03/2000	1646	755	06803.0008	12	35	9

Finnegan Henderson Farabow Garrett & Dunner LLP  
1300 I Street NW  
Washington, DC 20005-3315

## FILING RECEIPT



\*OC000000005539680\*

Date Mailed: 11/08/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Dirk Heinegard, Lund, SWEDEN;  
Pilar Lorenzo, Lund, SWEDEN;

## Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/142,054 07/02/1999

## Foreign Applications

If Required, Foreign Filing License Granted 08/28/2000


\*\* SMALL ENTITY \*\*

## Title

Cartilage intermediate layer protein and nucleic acids therefor  
^

## Preliminary Class

514



Data entry by : DAVENPORT, BOBBIE

Team : OIPE

Date: 11/08/2000





**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**RECEIVED**  
 MAR 08 2001  
 TECH CENTER 1600

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

## FILE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



Bib Data Sheet

<b>SERIAL NUMBER</b> 09/609,383	<b>FILING DATE</b> 07/03/2000 <b>RULE</b> -	<b>CLASS</b> 514	<b>GROUP ART UNIT</b> 1646 1644	<b>ATTORNEY DOCKET NO.</b> 06803.0008
<b>APPLICANTS</b> Dirk Heinegard, Lund, SWEDEN; Pilar Lorenzo, Lund, SWEDEN; <i>ok, pnt</i>				
<b>** CONTINUING DATA *****</b> THIS APPLN CLAIMS BENEFIT OF 60/142,054 07/02/1999 <i>ok, pnt</i>				
<b>** FOREIGN APPLICATIONS *****</b> <i>None, pnt</i>				
<b>IF REQUIRED, FOREIGN FILING LICENSE</b> <b>GRANTED ** 08/28/2000</b> <b>** SMALL ENTITY **</b>				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after met Verified and Acknowledged <i>Allowance</i> Examiner's Signature <i>[Signature]</i> Initials <i>[Initials]</i>		<b>STATE OR COUNTRY</b> SWEDEN	<b>SHEETS DRAWING</b> 12	<b>TOTAL CLAIMS</b> 35
				<b>INDEPENDENT CLAIMS</b> 7
<b>ADDRESS</b> Finnegan Henderson Farabow Garrett & Dunner LLP 1300 I Street NW Washington ,DC 20005-3315				
<b>TITLE</b> Cartilage intermediate layer protein and nucleic acids therefor				
<b>FILING FEE RECEIVED</b> 755	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	